{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95"}],"title":"Alive"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Deceased"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"}],"units":"Participants"}],"description":"Logistic regression will be used to analyze the association between standardized phase angle and 30 day mortality. 30 day mortality rate is defined as the percent of patients no longer alive at 30 days after registration.","groups":[{"description":"Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment. Patients with AML undergo a second measurement just prior to the nadir marrow. Patients also undergo bioelectrical impedance measurements prior to any invasive procedures (bone marrow biopsy, leukapheresis, PICC line placement, etc.).\n\nbioelectric impedance analysis: Undergo bioelectric impedance analysis","id":"OG000","title":"Diagnostic (Bioelectric Impedance Analysis)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"30 days","title":"Treatment Related Mortality Defined as the Percent of Patients no Longer Alive at 30 Days After Registration","type":"SECONDARY","unitOfMeasure":"Participants"}